SGEN
$SGEN
Seagen Inc.
Antibody-drug conjugate biotech company advancing targeted cancer therapies.
HealthcareAnalyst Rating
Hold
9 Buy / 14 Hold / 0 Sell
Subscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
SGEN — ADC platform, mixed fundamentals
Seagen ($SGEN) sits at a crossroads, with a mean analyst price target of $229 signaling upside while negative EPS and limited public financial detail inject caution. This report lays out the key catalysts, valuation context, and risks for retail investors.
Apr 6, 2026